Expect steady growth in biosimilars segment going forward, says Kiran Mazumdar Shaw of Biocon
âOverall, we have a nice basket of biosimilars for both the US and European market, which will set us up for a steady growth in that segment going forward,â said Shaw.from Moneycontrol Business News https://ift.tt/2D6iQRX
No comments: